Liver X receptor (LXR) modulators

A method of treating a disease, disorder, or condition in a mammal that would benefit from LXR modulation comprising administering to the mammal a compound of Formula (IA):

• or a pharmaceutically acceptable salt thereof, wherein:
• L1 is a bond;
• R1 is —OR9, —N(R9)2, C1-C6alkyl, C2-C6alkenyl, C1-C6haloalkyl, C2-C9heterocycloalkyl, —C(═O)R8, or —C(═O)N(R9)2;
• R2 is C1-C6alkyl, C2-C6alkenyl, C3-C8cycloalkyl, or —C1-C6alkyl-C3-C8cycloalkyl;
• R3 is hydrogen or halogen;
• R4 is aryl;
• wherein aryl is substituted with at least one R11;
• each R5 is independently halogen, C1-C6alkyl, or C1-C6haloalkyl;
• R8 is C1-C6alkyl, C2-C6alkenyl, C1-C6haloalkyl, —C1-C6alkyl-aryl, aryl, or heteroaryl;
• each R9 is independently hydrogen, C1-C6alkyl, or C1-C6haloalkyl;
• each R10 is independently hydrogen or C1-C6alkyl;
• each R11 is independently halogen, nitro, —OR10, —N(R10)2, —CN, —C(═O)R10, —C(═O)OR10, —C(═O)N(R10)2, —NR10C(═O)R10, —NR10SO2R10, —SOR10, —SO2R10, —SO2N(R10)2, —C(═O)OCH2SCH3, optionally substituted C1-C6alkyl, or optionally substituted C1-C6haloalkyl;
• wherein at least one R11 is —NR10SO2R10, —SOR10, —SO2R10, or —SO2N(R10)2;
• and
• n is 0.